News
IOBTQ
0.0082
-82.92%
-0.0398
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1d ago
Weekly Report: what happened at IOBT last week (0330-0403)?
Weekly Report · 1d ago
Why Applied Optoelectronics Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
Benzinga · 4d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 6d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 6d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 03/31 17:05
BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences
Reuters · 03/31 16:19
Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook
Benzinga · 03/31 16:07
IO Biotech Files Chapter 7, Ceases Operations, Liquidates
TipRanks · 03/31 15:15
Why Are Shares Of IO Biotech Plummeting?
Benzinga · 03/31 15:09
Dow Jumps 400 Points; TD Synnex Posts Upbeat Earnings
Benzinga · 03/31 13:42
IO Biotech Files Chapter 7 Bankruptcy And Ceases Operations In Delaware; Common Stockholders Unlikely To Receive Payment Or Distribution After Bankruptcy; Terminates All Employees And Officers Including CEO And CFO
Benzinga · 03/31 12:26
IO BIOTECH INC - COMMON STOCKHOLDERS UNLIKELY TO RECEIVE PAYMENT OR DISTRIBUTION AFTER BANKRUPTCY - SEC FILING
Reuters · 03/31 12:12
IO BIOTECH INC - CHAPTER 7 TRUSTEE APPOINTMENT TRIGGERS DEFAULT UNDER EIB FINANCE CONTRACT FOR EUR22.5 MLN - SEC FILING
Reuters · 03/31 12:12
NASDAQ TRADE HALT <IOBT.O> HALT NEWS PENDING AT 07:55 AM
Reuters · 03/31 11:55
More
Webull provides a variety of real-time IOBTQ stock news. You can receive the latest news about Io Biotech, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IOBTQ
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.